References
- Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomarkers Prev. 2016;25(1):16–27.
- Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953.
- Thun MJ, DeLancey JO, Center MM, et al. The global burden of cancer: priorities for prevention. Carcinogenesis. 2009;31(1):100–110.
- Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2019;69(5):363–385.
- Cox HL, Laupland KB, Manns BJ. Economic evaluation in critical care medicine. J Crit Care. 2006;21(2):117–124.
- Higgins AM, Harris AH. Health economic methods: cost-minimization, cost-effectiveness, cost-utility, and cost-benefit evaluations. Crit Care Clin. 2012;28(1):11–24.
- Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397–409.
- Woods B, Sideris E, Palmer S, et al. Nice dsu technical support document 19: partitioned survival analysis for decision modelling in. 2017.
- Coyle D, Coyle K. The inherent bias from using partitioned survival models in economic evaluation. Value Health. 2014;17(3):A194.
- Beca J, Hoch JS. Exploring the impact of structural uncertainty in partitioned survival models for oncology. Value Health. 2014;17(3):A205–A206.
- Bullement A, Cranmer HL, Shields GE. A review of recent decision-analytic models used to evaluate the economic value of cancer treatments. Appl Health Econ Health Policy. 2019;17(6):771–780.
- Woods BS, Sideris E, Palmer S, et al. Partitioned survival and state transition models for healthcare decision making in oncology: where are we now? Value Health. 2020;23(12):1613–1621.
- Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS)—explanation and elaboration: a report of the ISPOR health economic evaluation publication guidelines good reporting practices task force. Value Health. 2013;16(2):231–250.
- Goeree R, Villeneuve J, Goeree J, et al. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. J Med Econ. 2016;19(6):630–644.
- Gibson EJ, Begum N, Koblbauer I, et al. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. J Med Econ. 2019;22(6):531–544.
- Lee D, Amadi A, Sabater J, et al. Can we accurately predict cost effectiveness without access to overall survival data? The case study of nivolumab in combination with ipilimumab for the treatment of patients with advanced melanoma in England. PharmacoEcon Open. 2019;3(1):43–54.
- Rui M, Shi F, Shang Y, et al. Economic evaluation of cisplatin plus gemcitabine versus paclitaxel plus gemcitabine for the treatment of first-line advanced metastatic triple-negative breast cancer in China: using Markov model and partitioned survival model. Adv Ther. 2020;37(9):3761–3774.
- Williams C, Lewsey JD, Mackay DF, et al. Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and Markov decision-analytic modeling. Med Decis Making. 2016;37(4):427–439.
- Gao L, Li S-C. Modelled economic evaluation of nivolumab for the treatment of second-line advanced or metastatic squamous non-small-cell lung cancer in Australia using both partition survival and Markov models. Appl Health Econ Health Policy. 2019;17(3):371–380.
- CADTH. Trifluridine-tipiracil (lonsurf) for gastric cancer — details. 2020. [cited 2020 Nov 11]. Available from: https://www.cadth.ca/sites/default/files/pcodr/Reviews2020/10197TrifluridineTipiracilGC_inEGR_NOREDACT-ABBREV_EC24Mar2020_final.pdf
- CADTH. Keytruda for melanoma adjuvant treatment – details. 2020. [cited 2020 Nov 11]. Available from: https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10168PembrolizumabMAT_fnEGR_NOREDACT-ABBREV_Post_01Aug2019_final.pdf
- CADTH. Revlimid (in combo) bortezomib + dexamethasone for newly diagnosed multiple myeloma – details. 2020. [cited 2020 Nov 11]. Available from: https://www.cadth.ca/sites/default/files/pcodr/Reviews2019/10141LenalidomideBorDexMM_fnEGR_NOREDACT-ABBREV_EC-Post_19Jun2019_final.pdf.
- CADTH. Zykadia for non-small cell lung cancer (resubmission) – details. 2020. [cited 2020 Nov 11]. Available from: https://www.cadth.ca/sites/default/files/pcodr/pcodr_ceritinib_zykadia_nsclc_fn_egr.pdf
- CADTH. Avastin (with capecitabine) for metastatic colorectal cancer – details. 2020. [cited 2020 Nov 11]. Available from: https://www.cadth.ca/sites/default/files/pcodr/pcodr_avastin_capecitabine_mcrc_fn_egr.pdf
- CADTH. Pembrolizumab (keytruda) classical Hodgkin lymphoma – details. 2020. [Cited 2020 Nov 11]. Available from: https://www.cadth.ca/sites/default/files/pcodr/pcodr_pembrolizumab_keytruda_chl_fn_egr.pdf
- Ting Zhou A-XM, Fu L-Y. Discussion on the calculation of Markov model transition probability in pharmacoeconomics evaluation. Chin Health Econ. 2017;36(12):40–42.
- Ting Zhou A-XM. The survival analysis applied in calculation of Markov model transition probability in pharmaceutical evaluation. Chin J Evidence Based Med. 2018;18(10):1129–1134.